Journal Article

Serum Bactericidal Activity of the Methoxyfluoroquinolones Gatifloxacin and Moxifloxacin against Clinical Isolates of <i>Staphylococcus</i> Species: Are the Susceptibility Breakpoints Too High?

Gary E. Stein, Sharon Schooley and Glenn W. Kaatz

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 37, issue 10, pages 1392-1395
Published in print November 2003 | ISSN: 1058-4838
Published online November 2003 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/379518
Serum Bactericidal Activity of the Methoxyfluoroquinolones Gatifloxacin and Moxifloxacin against Clinical Isolates of Staphylococcus Species: Are the Susceptibility Breakpoints Too High?

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Healthy volunteers received a single dose of gatifloxacin and moxifloxacin (400 mg each), and serum samples were obtained from these volunteers over a 24-h period. Prolonged (⩾12 h) serum bactericidal activity (SBA) was observed for both agents against staphylococcal isolates with minimum inhibitory concentrations (MICs) of gatifloxacin of ⩽0.5 µg/mL. In strains with gatifloxacin MICs of 1.0 µg/mL, SBA was observed for ⩽6 h, and, for isolates with gatifloxacin MICs of 2.0 µg/mL, little or no SBA was observed for either drug. The relative lack of SBA against less susceptible strains of staphylococci suggests that the current susceptibility breakpoint concentration (MIC, 2.0 µg/mL) for these methoxyfluoroquinolones against Staphylococcus is too high.

Journal Article.  1864 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.